Navigation Links
NuVasive Acquires First Stem Cell Bone Graft Substitute
Date:5/14/2008

New technologies will drive US bone graft substitute market to reach almost

$1.9 billion by 2012, according to Millennium Research Group

WALTHAM, Mass., May 14 /PRNewswire/ -- With the acquisition of Osiris Therapeutics' Osteocel business, NuVasive has obtained the first off-the-shelf bone graft substitute (BGS) product to incorporate viable stem cells. Mounting surgeon excitement about this new BGS and other innovative products will drive the BGS market to $1.9 billion in 2012, according to Millennium Research Group's US Markets for Orthopedic Biomaterials 2008 report.

"The popularity of advanced BGS technologies has increased competition within the field. Medtronic Spinal and Biologics' INFUSE BGS, based on a recombinant human bone morphogenetic protein, has forced NuVasive and other BGS competitors to dramatically innovate," says Kevin Flewwelling, Orthopedics Research Manager at Millennium Research Group. "In 2007, INFUSE sales exceeded $700 million in the US and NuVasive saw an opportunity to compete against this very successful product."

In order to compete against these advanced BGS, other manufacturers of traditional BGS products -- such as demineralized bone matrices and synthetics -- are developing next-generation products that offer improved ease-of-use and superior bone healing and regrowth. Companies claim that these new features eliminate the need for autograft bone harvested from the patient's iliac crest, reducing postoperative pain and morbidity at the donor site. With these greater advantages, surgeons are shifting towards these newer devices. A survey of surgeons conducted by Millennium Research Group found that 30.3% expected to perform fewer procedures using only autograft bone by 2012.

In addition to the BGS market, the US Markets for Orthopedic Biomaterials 2008 report covers the hyaluronic acid viscosupplementation, machined bone interbody device, knee cartilage repair, and cell concentration system markets. The report also provides coverage of all key industry competitors, including AlloSource, Biomet, Blackstone Medical/Orthofix, DePuy, Exactech, Ferring Pharmaceuticals, Genzyme Biosurgery, Integra LifeSciences/IsoTis, LifeNet Health, Medtronic Spinal and Biologics, Musculoskeletal Transplant Foundation, Orthovita, Osiris Therapeutics, Osteotech, RTI Biologics, sanofi-aventis, Smith & Nephew, Stryker, Synthes, and Wright Medical Technology. Other reports in this series cover Europe (France, Germany, Italy, Spain, and the UK) and Japan.

About Bone Graft Substitutes

BGS are classified under the broader term of bone grafts. Bone grafts are used to promote bone healing and regrowth and fill bone voids in spinal fusion, trauma surgery, joint revision and reconstruction, and craniomaxillofacial surgery. These products can be classified into six categories: autograft, nonproprietary allograft, demineralized bone matrix, synthetics, growth factors -- such as bone morphogenetic proteins -- and stem cell products. Autograft is the only bone graft material that is taken from a patient's own body. Other bone graft materials are commonly referred to as BGS.

About Millennium Research Group

Millennium Research Group (http://www.MRG.net), a Decision Resources, Inc. company (http://www.DecisionResources.com), is the global authority on medical technology market intelligence and a leading provider of strategic information to the health care sector. Focused solely on the medical device, pharmaceutical, and biotechnology industries, the company provides its clients with the benefits of its specialized industry expertise through published reports and customized consulting services.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Amy Krohn

Millennium Research Group

416-364-7776 x101

akrohn@mrg.net


'/>"/>
SOURCE Millennium Research Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. NuVasive to Present at ThinkEquity Partners 5th Annual Growth Conference
2. NuVasive Announces Web Cast and Conference Call of Third Quarter 2007 Results
3. NuVasive Licenses Its Insert and Rotate Technology
4. NuVasive Cancels 10/24/07 Investor Reception Due to Concerns Over Southern California Fires
5. NuVasive to Present at BIOCOM Investor Conference 2007
6. NuVasive Announces Preliminary Unaudited Full Year 2007 Financial Results
7. NuVasive to Offer $200 Million Convertible Senior Notes Due 2013
8. NuVasive Prices $200 Million Convertible Senior Notes Due 2013
9. NuVasive Reports First Quarter 2008 Financial Results
10. Cogdell Spencer Inc. Acquires Summit Professional Plaza I and II in Brunswick, Georgia
11. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... One of Australia,s successful biotechnology ... a new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ... to list on the ASX. Noxopharm is a clinic-ready ... a Phase 1 clinical study later this year. ... the biggest problems facing cancer patients - the ability of cancers ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: